In contrast to the mutual exclusivity of mutations in oncogenes KRAS and BRAF, cancers with PIK3CA mutations have often concomitant mutations in either of these genes of the KRAS/BRAF/MEK/ERK pathway. The gene discussed is KRAS; the disease is cancer.